Image: Permanent Representation of Austria to the EU
Cape Bio Pharms to scale up inhalant that blocks SARS-CoV-2 infection
A South African biotechnology company will use relatives of the tobacco plant to produce a Covid-19 medicine developed by Austrian scientists.
A 15 February deal will see Cape Bio Pharms in Cape Town produce inhalable molecules that can block SARS-CoV-2 from infecting human cells when administered directly into the airways.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.